Zalutumumab Biosimilar, Anti-human EGFR Monoclonal Antibody

Zalutumumab Biosimilar, Anti-human EGFR Monoclonal Antibody

$175.00$1,200.00

In stock

$175.00$1,200.00

The cheapest research grade zalutumumab biosimilar (anti-human EGFR monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by zalutumumab. The research grade zalutumumab biosimilar protein is for research use only.

SKU: C067P
Clear
View cart
Catalog No. C067P
Product NameZalutumumab Biosimilar, Anti-human EGFR Monoclonal Antibody
Supplier Name Syd Labs, Inc.
Brand Name Syd Labs
Source/Host The anti-human EGFR monoclonal antibody zalutumumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity The research grade zalutumumab biosimilar specifically binds to the human epidermal growth factor receptor (EGFR).
Applications ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by zalutumumab.
Form Of Antibody 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin < 0.1 EU per 1 ug of the protein by the LAL method.
Purity >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping The research grade zalutumumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Order Offline Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

C067P: Zalutumumab Biosimilar (Research Grade), Anti-human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Zalutumumab Biosimilar uses the same protein sequences as the therapeutic antibody zalutumumab.

Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody directed towards the epidermal growth factor receptor (EGFR, also known as ErbB1/HER1). Zalutumumab is derived from transgenic mice immunized with A431-derived EGFR. Zalutumumab has undergone pre-clinical and Phase I and II studies and is also in Phases I and II for SCCHN front-line with chemo-radiation and SCCHN with radiation.

EGFR is a 170 kDa transmembrane glycoprotein composed of a single polypeptide chain. It belongs to the ErbB receptor family, also known as the EGF receptor family. The binding of EGF at the cell surface induces the dimerization of EGFR, which results in the activation of EGFR tyrosine kinase activity and receptor trans-autophosphorylation. Sites of tyrosine autophosphorylation in the activated EGFR interact with downstream signaling proteins to form large signaling complexes. The receptor-signaling protein complexes then initiate the activation of various signaling pathways, and eventually stimulate cell proliferation and survival. Zalutumumab acts via two distinct mechanisms. First, as an inverse agonist, it specifically binds to the EGFr domain III on the cell surface and competitively inhibits the ligand binding of EGF and TGF-a to EGFR. It then blocks receptor activation by restricting the molecule’s conformational flexibility: In the inactive conformation, the intracellular tyrosine kinase domains of EGFR molecules are spatially separated to an extent that prevents receptor dimerization and phosphorylation. The EGFR cascade cannot be started. This mechanism was found to be effective in established xenograft models at doses giving full receptor occupancy. Second, in contrast to panitumumab, which is an IgG2 antibody, Zalutumumab has been shown to arrest tumor growth and induce tumour regression in animal disease models even at very low, subsaturation antibody concentration. This antitumor effect is mediated by antibody-dependent cellular cytotoxicity (ADCC): The fragment antigen binding (Fab) region of the antibody binds to the antigen on EGFR-expressing tumor cells. Through an immunological response, the body’s NK lymphocytes recognize and bind to the Fc portion on the antibody through an Fc receptor, CD16. The NK cell is then activated through cross-linking of Fc receptors which sends a signal to induce apoptosis. A recent study showed that this mechanism of action might be important in preventing tumour outgrowth or metastasis in vivo, even in cancers insensitive to EGFR signaling inhibition.

Syd Labs also provides the following anti-EGFR antibody biosimilar proteins:

Cetuximab Biosimilar, research grade, anti-human EGFR monoclonal antibody
Cetuximab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant
Matuzumab Biosimilar, research grade, anti-human EGFR monoclonal antibody
Nimotuzumab Biosimilar, research grade, anti-human EGFR monoclonal antibody
Panitumumab Biosimilar, research grade, anti-human EGFR monoclonal antibody
Panitumumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant

Syd Labs provides a number of research grade antibody biosimilar proteins with competitive prices starting from $3/mg. Syd Labs also introduces mutations to the antibody biosimilars including engineering or switching the isotypes or Fc engineering, such as Fc silent.

Syd Labs also produces the in vivo grade isotype control antibodies. Some customers purchase them for in vitro assays such as flow cytometry or immunohistochemistry (IHC) because the prices are too good if compared to those research reagents of antibody isotype controls . Syd Labs provides the following in vivo grade recombinant human IgG1 kappa isotype control antibody proteins and mutants:

In vivo grade recombinant human IgG1 isotype control antibody
In vivo grade recombinant human IgG1 Fc protein
In vivo grade recombinant human IgG1-D265A isotype control antibody
In vivo grade recombinant human IgG1-N297A isotype control antibody
In vivo grade recombinant human IgG1-D265A N297A isotype control antibody
In vivo grade recombinant human IgG1-L234A L235A P329G (LALAPG) isotype control antibody

Frequent questions related to “research grade zalutumumab biosimilar, anti-human EGFR monoclonal antibody”:

Does zalutumumab bind mouse EGFR?
Is zalutumumab humanized?
What is the mechanism of action for zalutumumab?

Popular searches related to “research grade zalutumumab biosimilar, anti-human EGFR monoclonal antibody”:

zalutumumab monoclonal antibody
zalutumumab purchase
zalutumumab mechanism of action
zalutumumab price
EGFR mouse cell line
epidermal growth factor receptor
Zalutumumab Biosimilar Research Grade
EGFR

Additional information

Size

1 mg, 20 mg, 5 mg

No more offers for this product!